8-K: OpGen Granted Nasdaq Extension to File Delinquent Quarterly Report

OpGen, Inc. has been granted an extension by the Nasdaq Hearings Panel to file its overdue Form 10-Q by July 8, 2024, to maintain its listing.

Summary

• OpGen, Inc. received a notice from Nasdaq for being delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024.
• The company submitted a plan to address this delinquency.
• The Nasdaq Hearings Panel granted OpGen's request for continued listing, contingent on filing the Form 10-Q by July 8, 2024.
• OpGen intends to file the report as soon as practicable, but there is no guarantee of the exact filing date.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the company's failure to file its quarterly report on time and the risk of delisting, although an extension has been granted.

Positives

• The Nasdaq Hearings Panel granted OpGen's request for continued listing.
• OpGen has been given an extension until July 8, 2024, to file its overdue Form 10-Q.

Negatives

• OpGen was initially notified by Nasdaq for being delinquent in filing its Q1 2024 report.
• There is no guarantee of the exact date the Form 10-Q will be filed.

Risks

• The company's continued listing on Nasdaq is contingent on filing the Form 10-Q by July 8, 2024.
• Failure to meet the deadline could result in delisting from Nasdaq.
• The company acknowledges that its forward-looking statements are subject to risks and uncertainties.

Future Outlook

The company intends to file its Form 10-Q as soon as practicable, but there is no assurance of the definitive filing date. The company's continued listing on Nasdaq is dependent on meeting the July 8, 2024 deadline.

Management Comments

• The company plans to file its Form 10-Q as soon as practicable.

Industry Context

This announcement highlights the importance of timely financial reporting for companies listed on exchanges like Nasdaq. Delays in filing can lead to compliance issues and potential delisting, impacting investor confidence.

Comparison to Industry Standards

• Many companies listed on Nasdaq are required to file quarterly reports within a specific timeframe.
• Failure to meet these deadlines can result in similar notices of non-compliance and potential delisting.
• Companies like Lumos Pharma and Athersys have also faced similar compliance issues with Nasdaq in the past, highlighting the importance of maintaining timely financial reporting.

Stakeholder Impact

• Shareholders are impacted by the uncertainty surrounding the company's Nasdaq listing.
• Employees may be concerned about the company's financial stability and future prospects.
• Creditors may be wary of the company's ability to meet its obligations.

Next Steps

• OpGen needs to file its Form 10-Q by July 8, 2024, to maintain its Nasdaq listing.

Key Dates

Keywords

Nasdaq, delisting, Form 10-Q, compliance, quarterly report, listing rule, extension